Evidence map›Paper›PMID 40990867›Full record

ArticleInvestigative ophthalmology & visual science2025

Evaluating the Optic Nerve Crush Model to Understand the Function of Microglia in Glaucoma Neuroprotection.

Xiaowu Gu, Tom Truong, Tiffany Heaster-Ford, Tae-Hoon Kim, Gyeong Jin Kang, Joanna Yung, Miriam Baca, Shawnta Y Chaney, Jeffrey W Hofmann, Jeffrey Eastham and 1 more

Abstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Neuroinflammation in glaucoma: a myriad of cellular pathways and players.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaowu GuDepartment of Neuroscience, Genentech, Inc., South San Francisco, California, United States.
Tom TruongDepartment of Translational Immunology, Genentech, Inc., South San Francisco, California, United States.
Tiffany Heaster-FordDepartment of Translational Imaging, Genentech, Inc., South San Francisco, California, United States.
Tae-Hoon KimDepartment of Translational Imaging, Genentech, Inc., South San Francisco, California, United States.
Gyeong Jin KangDepartment of Translational Immunology, Genentech, Inc., South San Francisco, California, United States.
Joanna YungDepartment of Research Pathology, Genentech, Inc., South San Francisco, California, United States.
Miriam BacaDepartment of Research Pathology, Genentech, Inc., South San Francisco, California, United States.
Shawnta Y ChaneyDepartment of Translational Immunology, Genentech, Inc., South San Francisco, California, United States.
Jeffrey W HofmannDepartment of Research Pathology, Genentech, Inc., South San Francisco, California, United States.
Jeffrey EasthamDepartment of Research Pathology, Genentech, Inc., South San Francisco, California, United States.
Marion JeanneDepartment of Neuroscience, Genentech, Inc., South San Francisco, California, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Microgliosis is a key neuroinflammatory feature in human glaucomatous retinas, believed to contribute to disease progression. This study aims to characterize changes in microglia and intra-retinal axons following optic nerve crush (ONC) and investigate microglial involvement in retinal ganglion cell (RGC) and axonal degeneration. Methods: Using the CD11c.YFP.Venus.Tg mouse line, we tracked microglial activation and assessed the spatiotemporal changes in TUJ1+ intraretinal axons over a 2-week period post-ONC. Microglial function was examined by depleting microglia with the CSF1R inhibitor PLX5622 and using Trem2-deficient mice with dampened microglial activation. Results: Activated microglia accumulated significantly in the retina from day 4 post-ONC, peaking at day 7. Retinal microglia became hypertrophic by day 1 and started proliferating. Axon beading occurred primarily in the peripheral retina by day 2 post-ONC, with more beaded axons appearing along long axonal bundles toward the optic nerve head (ONH) by day 7 and day 14. There was a significant reduction in overall TUJ1 expression and axonal bundle thickness during this period. Despite complete microglial depletion and significantly reduced activation, no differences were observed in the RGC count or the extent of optic nerve damage following ONC. Conclusions: Microglial activation is secondary to axonal injury and plays a bystander role in the ONC model. Robust RGC and axonal degeneration appear unaffected by activated microglia. This finding challenges the utility of the ONC model for evaluating microglia-based glaucoma treatments. Additionally, the study reaffirms the value of combining fluorescent reporter mouse lines with noninvasive ocular imaging for streamlining future research.

Indexed as

GlaucomaMicrogliaNerve CrushNeuroprotectionOptic Nerve InjuriesRetinal Ganglion CellsAnimalsAxonsDisease Models, AnimalMiceMice, Inbred C57BLMice, TransgenicOrganic ChemicalsOrganic ChemicalsPLX5622

Identifiers

PMID40990867
PMCPMC12476160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.